Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

directrx - fenofibrate (unii: u202363uos) (fenofibrate - unii:u202363uos) - fenofibrate 160 mg - - treatment of hypercholesterolemia fenofibrate tablets, usp are indicated as adjunctive therapy to diet to reduce elevated ldl-c, total-c, triglycerides and apo b, and to increase hdl-c in adult patients with primary hypercholesterolemia or mixed dyslipidemia (fredrickson types iia and iib). lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see national cholesterol education program [ncep] treatment guidelines, below). treatment of hypertriglyceridemia fenofibrate tablets, usp are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (fredrickson types iv and v hyperlipidemia). improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. markedly elevated levels of serum

Καναδάς - Αγγλικά - Health Canada

mint pharmaceuticals inc - fenofibrate - tablet - 145mg - fenofibrate 145mg - fribic acid derivatives

Καναδάς - Αγγλικά - Health Canada

teva canada limited - fenofibrate - tablet - 100mg - fenofibrate 100mg - fribic acid derivatives

Καναδάς - Αγγλικά - Health Canada

teva canada limited - fenofibrate - tablet - 160mg - fenofibrate 160mg - fribic acid derivatives

Καναδάς - Αγγλικά - Health Canada

pharmel inc - fenofibrate - tablet - 100mg - fenofibrate 100mg - fribic acid derivatives

Καναδάς - Αγγλικά - Health Canada

pharmel inc - fenofibrate - tablet - 160mg - fenofibrate 160mg - fribic acid derivatives

Καναδάς - Αγγλικά - Health Canada

mylan pharmaceuticals ulc - fenofibrate - capsule - 200mg - fenofibrate 200mg - fribic acid derivatives

Καναδάς - Αγγλικά - Health Canada

pharmascience inc - fenofibrate - capsule - 200mg - fenofibrate 200mg - fribic acid derivatives

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

a-s medication solutions - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate 145 mg - fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (ldl-c), total cholesterol (total-c), triglycerides (tg) and apolipoprotein b (apo b), and to increase high-density lipoprotein cholesterol (hdl-c) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. fenofibrate tablets are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. markedly elevated levels of serum triglycerides (e.g. >2000 mg/dl) may increase the risk of developing pancreatitis. the effect of fenofibrate therapy on reducing this risk has not been adequately studied. fenofibrate at a dose equivalent to 145 mg of fenofibrate tablets was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

lupin limited - fenofibrate (unii: u202363uos) (fenofibric acid - unii:bgf9mn2hu1) - fenofibrate 48 mg - fenofibrate tablets usp are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (ldl-c), total cholesterol (total-c), triglycerides and apolipoprotein b (apo b), and to increase high-density lipoprotein cholesterol (hdl-c) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. fenofibrate tablets usp are  is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. markedly elevated levels of serum triglycerides (e.g. >2,000 mg/dl) may increase the risk of developing pancreatitis. the effect of fenofibrate therapy on reducing this risk has not been adequately studied. fenofibrate at a dose equivalent to 145 mg of fenofibrate tablets usp was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patient